All that's happening in generics
Generics bulletin provides its subscribers with up-to-date commercial intelligence about business opportunities in the global generic medicines and biosimilars markets.
Accurate and reliable news reports reveal the strategies of the world’s leading generics companies and analyse their business performance, plans and product portfolios.
Patent and pricing issues, regulatory changes, government initiatives, market opportunities and industry consolidation provide the wider context for Generics bulletin’s comprehensive industry coverage.
With subscribers in nearly 60 countries, Generics bulletin is read by senior executives in all of the world’s leading generics companies, as well as by industry watchers and those supplying active ingredients, goods and services to the global generic medicines industry.
An annual subscription comprises:
- 20 Generics bulletin newsletters;
- AND at least 46 weekly News@Genericsbulletin email newsflashes containing the week’s top news stories.
Choice of formats
Generics bulletin newsletter is available:
- in traditional hard-copy print format delivered by airmail
- now as the digital edition Generics bulletin-i–for either Apple or Android mobile devices – that provides the same commercial intelligence on the move. (Suitable for operating systems Apple iOS 5.0 and above; Android 2.2 and above)
The digital edition Generics bulletin-i has two significant benefits – it is available on the day of publication with no postal delay; and it contains a fully word-searchable archive containing over 100 Generics bulletin editions dating back to 2008.
Subscribers may subscribe to either or both formats.
A corporate subscription provides company-wide access to Generics bulletin or Generics bulletin-i. In either case, such a Global Site Licence ensures availability on the day of publication. Please contact us at the address below for further details.